Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VERT-002 in Advanced Solid Tumors and NSCLC with MET Alterations
NCT06669117Phase 2Recruiting
- Sponsor
- Pierre Fabre Laboratories
- Start
- Oct 2024
- Primary completion
- Oct 2030
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 9
01
Overview
Phase 2, open-label, single-arm trial of vert-002 in solid tumor and non-small cell lung cancer (NSCLC), sponsored by Pierre Fabre Laboratories. Primary endpoints: Treatment Emergent Adverse Events, Incidence of TEAEs/SAEs leading to dose modification and 4 more. Started Oct 2024; status: recruiting.
02
Drugs
vert-002
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06669117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06669117.